Found vs Noom Med: GLP-1 Weight Loss Programs Compared (2026)
An independent, side-by-side comparison of Found and Noom for GLP-1 weight loss programs — pricing, medications, protocols, and patient experience.

Quick Verdict
Best Price
Found
Starting at $149/mo vs $199/mo
Most Medications
Found
2 medications vs 2
Best for Beginners
Found
Video Telehealth, fast onboarding
Head-to-Head Comparison
Pricing Breakdown
Side-by-side pricing for every medication.
| Medication | Found | Noom | Savings |
|---|---|---|---|
| Semaglutide | $149/monthly | $199/monthly | Save $50/mo with Found |
| Tirzepatide | $399/monthly | Not offered | Only at Found |
Pros and Cons
Found
- Holistic approach — medication + coaching + community
- Board-certified obesity medicine specialists
- Competitive compounded semaglutide pricing
- Personalized weight-loss plans with behavior change focus
- Slower shipping than competitors (5-7 days)
- No lab testing included
- Coaching quality can vary
- Limited to weight-loss medications only
Noom
- Unique combination of GLP-1 medication with an established CBT-based behavior-change curriculum
- Video consultations required (more thorough clinical evaluation than async providers)
- Over a decade of behavior-change coaching experience predating the medication program
- Personal coach and group coaching included in the price
- Competitive compounded semaglutide pricing ($149/month) for what's included
- Cannot opt out of the coaching/app component to lower cost
- Noom Med is relatively new (launched 2023)
- No published clinical trial data specifically for the combined Med + coaching program
- No lab testing included
- Pricing has been volatile
How They Compare
Our editorial assessment across key dimensions.
In-Depth Comparison
By sarah-chen · Last updated April 14, 2026
Found vs Noom Med: GLP-1 Weight Loss Programs Compared
Found and Noom Med both position themselves as behavioral + medication programs rather than pure GLP-1 dispensaries. But they approach this differently: Found offers a broad multi-medication menu with a flexible, individualized approach, while Noom Med applies its proprietary CBT-based app curriculum as the behavioral layer on top of GLP-1 medication. Here is how they compare on every dimension.
Quick Verdict
| Found | Noom Med | |
|---|---|---|
| Monthly cost | ~$99–199/month | $149/month |
| Medications available | GLP-1s + non-GLP-1 options (metformin, naltrexone-bupropion, etc.) | Semaglutide only |
| Best for | Multi-medication options; flexibility; cost | CBT behavioral curriculum; patients who tried medication alone before |
| Behavioral approach | Personalized plan + app | Structured CBT curriculum (Noom app) |
| Tirzepatide | Limited | No |
| Insurance navigation | Limited | No |
The Core Difference
Found's philosophy: Weight is complex and multi-factorial. Not every patient responds to the same medication. Found offers a broader menu of options — GLP-1s, non-GLP-1 medications (metformin, naltrexone-bupropion, topiramate), and combination approaches. The platform individuates treatment based on your metabolic profile and response.
Noom Med's philosophy: Behavior change is the foundation; medication reduces the appetite noise so behavioral work can take effect. The Noom app delivers a CBT-based curriculum covering food psychology, habit formation, and emotional eating. The medication is a tool in the behavioral system.
Pricing
| Cost Component | Found | Noom Med |
|---|---|---|
| Monthly membership | ~$99–129/month | $149/month (includes medication) |
| Medication cost | Varies by medication type | Included |
| GLP-1 (compounded semaglutide) | Additional (typically $100–150/month extra) | Included in $149 |
| Non-GLP-1 medications | Often lower cost or included | Not available |
| Insurance navigation | Limited | No |
Important: Found's base price doesn't always include the medication. When you add compounded semaglutide, total cost can approach $200–250/month. If your goal is GLP-1 specifically, Noom Med's all-in pricing may be more straightforward.
However, if Found prescribes a non-GLP-1 medication (which some patients prefer or tolerate better), the total cost can be lower than $149/month.
Medication Flexibility: Found's Key Advantage
Found's broader medication menu is a genuine differentiator:
| Medication | Found | Noom Med |
|---|---|---|
| Compounded semaglutide | Yes | Yes |
| Brand-name Wegovy | Limited | No |
| Tirzepatide | Limited | No |
| Metformin | Yes | No |
| Naltrexone-bupropion (Contrave) | Yes | No |
| Phentermine | Yes | No |
| Topiramate | Yes | No |
| Combination protocols | Yes | No |
Who this matters for:
- Patients who can't tolerate GLP-1 side effects and want alternatives
- Patients who've already tried semaglutide and want a different approach
- Patients with specific metabolic or psychiatric comorbidities that make certain medications more appropriate
- Patients who want the lowest-cost entry point (non-GLP-1 medications can be cheaper)
Behavioral Support Comparison
| Feature | Found | Noom Med |
|---|---|---|
| App-based curriculum | Yes (personalized) | Yes (structured CBT) |
| Coaching style | Personalized health coach | Noom coach + group support |
| CBT methodology | Partial | Full Noom CBT curriculum |
| Food logging | Yes | Yes (Noom food database) |
| Meal planning | Basic | Structured |
| Community | Limited | Group sessions available |
| Exercise integration | Basic | Moderate |
The behavioral difference: Noom's CBT curriculum is more structured and has been validated across millions of users over years before Noom Med launched. Found's behavioral component is more flexible and personalized but less standardized.
Which is better depends on patient preference: some patients thrive with a clear daily curriculum (Noom); others prefer a flexible, coach-guided approach (Found).
Speed to Treatment
| Step | Found | Noom Med |
|---|---|---|
| Intake questionnaire | 10–15 minutes | 15–20 minutes |
| Medical review | 24–48 hours | 24–48 hours |
| Prescription and shipping | 3–7 days | 5–10 days |
| Total: first dose | ~5–10 days | ~7–14 days |
Both are mid-range for speed. Neither is as fast as Henry Meds or Ro (4–7 days). Neither is as slow as insurance-based programs.
Head-to-Head: Who Should Choose Which
Choose Found if:
- You want access to non-GLP-1 medication options alongside GLP-1s
- You've had GLP-1 side effects that made you want alternatives
- You want a personalized, flexible program rather than a structured curriculum
- You're interested in combination medication protocols
- Cost is a consideration and you may qualify for lower-cost medications
Choose Noom Med if:
- You want GLP-1 medication specifically (semaglutide)
- The CBT behavioral curriculum is appealing — you want to address the psychology of eating alongside medication
- You've tried GLP-1 alone (without behavioral support) and want more structure
- You want an all-in predictable monthly price
- The Noom brand and app track record give you confidence in the behavioral component
Neither May Be Right If...
| Situation | Better Option |
|---|---|
| You want the fastest start | Henry Meds or Ro (4–7 days) |
| You want tirzepatide | Ro or Henry Meds |
| You want insurance coverage | Sequence or FORM Health |
| You want deep specialist care | FORM Health or Calibrate |
| You want the cheapest cash-pay GLP-1 | Henry Meds ($129 after 6 months) |
Related Resources
- Best GLP-1 with Coaching — programs ranked by coaching depth
- Henry Meds vs Noom Med — Noom's price competitor
- Found vs Henry Meds — another Found comparison
- GLP-1 Alternatives FAQ — non-GLP-1 weight loss medications
- How Much Weight Can You Lose on GLP-1 — realistic expectations
Related Guides
Best GLP-1 Options After Foundayo Approval: Oral vs Injectable 2026
Read guide →Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care
The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.
Read guide →Is Compounded Semaglutide Legal and Safe in 2026?
Is compounded semaglutide still legal? We break down the current FDA rules, 30 new warning letters, SAFE Drugs Act, Hims exiting compounded, and what this means for your prescription.
Read guide →Compounded Tirzepatide 2026: What's Happening and What Patients Should Do
Compounded tirzepatide is under active FDA enforcement as of March 2026 — supply is declining but not yet at zero. The 503B enforcement discretion ended over a year ago (March 2025); the FDA has now issued 50+ warning letters including a 30-letter batch in March 2026. Here's what patients need to know and what to do.
Read guide →